Supercharged immune cells take on viruses in transplant patients

NCT ID NCT01325636

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether giving patients special immune cells (T cells) that target CMV or adenovirus could control these infections after a stem cell transplant. Sixteen children and adults received one or two doses of these cells. The goal was to reduce virus levels in the blood safely. The trial was early-stage, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: specific immune cells (CD4 and CD8 T cells) targeting CMV or adenovirus
What this could lead to: If it works, this could offer a way to control dangerous viral infections after stem cell transplants without relying on drugs that have side effects.
What could go wrong: This was a small, early-phase trial with only 16 patients, so results may not apply broadly. The treatment could also cause graft-versus-host disease or other immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOVIRUS INFECTIONS CYTOMEGALOVIRUS INFECTIONS

Contacts and locations

Locations

Biotherapy department, Hôpital Necker - Enfants Malades

Paris, 75743, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.